Recent Quotes (30 days)

You have no recent quotes
chg | %

Finance

Results 1 - 20 of about 23 for Novartis AG�
Company Exchange Symbol Last price Quote change Market cap
Valeant Pharmaceuticals Intl Inc NYSE VRX 96.61 -0.33 (-0.34%) 32.83B
Valeant Pharmaceuticals International, Inc. is a specialty pharmaceutical and medical device company. The Company is engaged in developing, manufacturing, ...
Novartis AG (ADR) NYSE NVS 74.27 -0.79 (-1.05%) 197.17B
Novartis AG is a holding company that, through its subsidiaries, is engaged in development, manufacturing and marketing of a range of healthcare products ...
Novartis AG VTX NOVN 73.90 -0.60 (-0.81%) 202.88B
Novartis AG is a holding company that, through its subsidiaries, is engaged in development, manufacturing and marketing of a range of healthcare products ...
Valeant Pharmaceuticals Intl Inc TSE VRX 134.34 +1.10 (0.83%) 45.84B
Valeant Pharmaceuticals International, Inc. is a specialty pharmaceutical and medical device company. The Company is engaged in developing, manufacturing, ...
NOVARTIS AG CHF0.50 (REGD) OTCMKTS NVSEF 73.40 -2.60 (-3.42%) 203.45B
Celgene Corporation NASDAQ CELG 97.89 -4.04 (-3.96%) 73.86B
Celgene Corporation (Celgene), together with its subsidiaries, is an integrated biopharmaceutical company engaged primarily in the discovery, ...
VALEANT PHARMACEUT. INTL FRA BVF 86.37 -1.35 (-1.54%)
NOVARTIS AG CEDEAR EACH REP 0.5 ADR BCBA NVS 0.000
MorphoSys AG ETR MOR 41.69 -0.80 (-1.88%) 1.09B
... development for diabetic nephropathy and fibrotic diseases, well as five programs in the discovery phase and two pre-development programs with Novartis.
Valeant Pharma SWX VRX 102.80 0.00 (0.00%)
Morphosys Ag (ADR) OTCMKTS MPSYY 23.51 0.00 (0.00%) 1.25B
... development for diabetic nephropathy and fibrotic diseases, well as five programs in the discovery phase and two pre-development programs with Novartis.
MorphoSys AG FRA MOR 41.92 -0.69 (-1.61%) 1.09B
... development for diabetic nephropathy and fibrotic diseases, well as five programs in the discovery phase and two pre-development programs with Novartis.
MORPHOSYS AG O.N. NEUE ETR MORN 17.48
MORPHOSYS AG O.N. NEUE FRA MORN 17.00
MORPHOSYS AG O.N. NEUE ETR MORA 0.0000
MORPHOSYS AG O.N. NEUE FRA MORA 37.00
CELGENE CORP. DL-,01 FRA CG3 91.61 +3.07 (3.47%)
Celgene Corp SWX CELG 102.50 0.00 (0.00%)
VALEANT PHARMACEUTICALS INTERNATIONAL, INC. BMV VRXN 1,777.00 0.00 (0.00%)
CELGENE CORP. DL-,01 ETR CG3 89.40 -2.07 (-2.26%)